Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Welcure Drugs & Pharmaceuticals considered a Letter of Intent from Telexcell Trade PTE LTD (Singapore) to acquire up to 25% equity at an indicative price of ₹20 per share, nearly double the prevailing market price of ~₹10. The Board unanimously rejected Telexcell's demand for any management influence or control rights, affirming that Welcure will remain independently managed. The acquisition, if it proceeds, must happen entirely through secondary market routes — open market purchases, block deals, or off-market share purchase agreements — meaning no new shares will be issued and there will be no dilution or liability for the company. The Board also clarified that no fund-raising (QIP, preferential allotment, or private placement) is planned at present, though Telexcell will get first priority as a preferred partner for any future capital raise.
Short-term positive: a foreign strategic investor validating the stock at nearly 2x market price signals confidence in intrinsic value. No dilution or balance sheet impact since the deal is secondary-market based, but any actual buying by Telexcell could support the stock price and trading volumes.